Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Springer

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Cancer Research|September 6, 2022
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung CancerRyohei Yoshida, Maria Saigi, Tetsuo Tani, et al.
Cancer Cell|September 23, 2022
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Cancer Research|September 6, 2022
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung CancerRyohei Yoshida, Maria Saigi, Tetsuo Tani, et al.
Cancer Cell|September 23, 2022
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Pageof 15